Abiopharma

🔍 Nouri Alaleh (Executive)

Company: PROCEPT BioRobotics Corp (PRCT)

Report Date: 2026-03-05

Detailed Transactions and Holdings:

• Acquired 43,811 shares of Common Stock (Direct)
  Date: 2026-03-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 121,156.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,892 shares of Common Stock at $23.7019 per share (Direct)
  Date: 2026-03-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 114,264.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 29,615 shares of Stock Option (Right to Buy) at $25.35 per share (Derivative)
  Date: 2026-03-05 | Code: A | Expires: 2036-03-04 | equity_swap_involved: 0 | shares_owned_after: 29,615.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. One-quarter of the RSUs shall vest on March 5, 2027, with onesixteenth of the remaining RSUs vesting quarterly over 36 months, subject to the Reporting Person continuing as a service provider through such date.
• F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units and Performance Stock Units.
• F3: 1/48th of the shares subject to the Stock Option shall vest monthly from the vesting commencement date of March 5, 2026, over a four year period, subject continued employment or service by the Reporting Person to the Issuer through the applicable vesting date.